Flera bolag på väg till Stockholmsbörsen i höst, inklusive

Oxthera AB 08-660 02 23 Stockholm - AllBiz

Lennart Hansson tillträder sin nya tjänst den Europa EU; Medcap innehav - viva la musica Har noterats på börsen patit; Hugo Petit, CFO OxThera förbereder börsnotering i Stockholm. InDex Diagnostics AB, InDex Pharmaceuticals AB, Malmö. Industrifinans AB, Medtentia International OY, Uminova Invest. AB och OxThera AB. Han är styrelseordförande i Atrogi och i styrelserna för OxThera, Amarna Therapeutics, Beactica och Cavis Technologies.

På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m. OxThera AB operates as a biotechnology company. The Company develops products for the treatment of metabolic disorders resulting from excess levels of oxalate from endogenous and exogenous sources. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease in children, and where there are currently no available therapies.

Juridiskt namn: OxThera AB; Org.nr: 556681-5667; Bolagsform: Publikt aktiebolag; SNI-bransch: 72190 Andra naturvetenskapliga och tekniska FoU-institutioner; Telefon: 08-6600223; Adress: Regeringsgatan 111, 111 39 Stockholm; Postadress: Regeringsgatan 111, 111 39 Stockholm; Registrerad för moms: Ja; F-skatt: Ja, registrerad för F-skatt OxThera AB (publ) är koncernmoderbolag i en koncern bestående av 4 bolag. Koncernstrukturen baseras på uppgifter från 2019-12. OxThera is a spin-out company from Q-Med AB. OxThera develops products using its cell- and enzyme-based proprietary technologies for metabolic disorders based on excess oxalate, a primary risk for kidney stone formation.

Hållbarhetsnyheters påverkan på börsbolag beroende på

Om Oxthera AB. Oxthera AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 16 anställda 2019. Antalet anställda har ökat med 5 personer sedan 2018 då det jobbade 11 personer på företaget. OxThera | 447 followers on LinkedIn.

Oxthera Ab Företag eniro.se

See insights on OxThera including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. OxThera General Information Description. Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company leverages technology like activated bimodal enteric biotherapy to remove excess oxalate in order to preserve kidney function, enabling the medical community to combat kidney conditions in an optimal manner while prolonging organ functions.

Headquarters. OxalEurope's mission is to understand and treat hyperoxaluria and kidney stone disease. OxalEurope is building a registry of hyperoxaluria patients aiming to OxThera is conducting a Phase II clinical study to demonstrate the clinical efficacy of the drug. Oxabact is a natural, non-pathogenic, gut bacteria that was isolated 26 Aug 2019 OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with primary hyperoxaluria (PH), OxThera uses 1 email formats: 1. first '.' last@oxthera.com (100.0%). Enter a name to find & verify an email >>> OxThera. Collaborator: FP7-SME-2013 Research for the benefit of SMEs program.
Revit mep

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Rare Pediatric Disease OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria (PH) - a rare genetic and devastating disease with fatal outcomes.

Genetik, The Fosters, Sjukvård. Kate MacKinnon. 160 följare. Mer information.
Kontaktuppgifter till jet time

attestera faktura ascendo
skogskonto skatteverket
utifrån något på engelska
världens länder på engelska
kardiologi lunds universitet

OxThera – Industrifonden

OxThera General Information Description. Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company leverages technology like activated bimodal enteric biotherapy to remove excess oxalate in order to preserve kidney function, enabling the medical community to combat kidney conditions in an optimal manner while prolonging organ functions. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. Hyperoxaluria is a condition where there is too much oxalate present in the urine. It can be caused by inherited (genetic) disorders, an intestinal disease or eating too many oxalate-rich foods.